This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E71.1 (other disorders of branched-chain amino-acid metabolism) | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | PA, Propionyl-CoA carboxylase deficiency, PCC deficiency, Ketotic hyperglycinemia (some) |
| C. Adult onset | Likelihood of first onset in adulthood: low — mostly presents in the neonatal period to infancy; some patients with mild variants may first be diagnosed in adulthood with a metabolic crisis or cardiomyopathy. |
| 1. History | 1961 Childs et al. first reported a case of ketoacidosis+hyperglycinemia → 1968 Hsia et al. identified propionyl-CoA carboxylase deficiency → 1990s PCCA/PCCB cloning → 2000s standardization of tandem mass screening. |
| 2. Causes | PCCA (13q32.3) or PCCB (3q22.3) gene mutations → propionyl-CoA carboxylase (PCC) deficiency → accumulation of toxic metabolites such as propionyl-CoA·propionic acid·methylcitric acid. |
| 3. Genetics | Autosomal recessive. PCCA (13q32.3), PCCB (3q22.3). High prevalence in Saudi Arabian·Greenland Inuit populations. Worldwide about 1/100,000–1/500,000. Various missense·nonsense·deletion variants. |
| 4. General epidemiology | Worldwide about 1/100,000–1/500,000. Saudi Arabia about 1/2,500 (effect of consanguineous marriage). Korea: a few per year through tandem mass screening. Males and females equal. |
| 5. Pathophysiology | PCC deficiency → propionyl-CoA accumulation → inhibition of the mitochondrial TCA cycle·urea cycle → ketoacidosis·hyperammonemia·hyperglycinemia; propionic acid neurotoxicity and oxidative stress → basal ganglia damage·cardiomyopathy. |
| 6. Symptoms | Neonatal period: poor feeding·lethargy·vomiting·metabolic ketoacidosis·hyperammonemia → death without treatment. Long-term complications: developmental delay·intellectual disability·basal ganglia damage·cardiomyopathy·pancreatitis·bone marrow suppression (pancytopenia). |
| 7. Signs | Elevated blood C3-acylcarnitine, increased urinary methylcitric acid·3-hydroxypropionic acid, elevated blood ammonia, metabolic ketoacidosis, pancytopenia, QTc prolongation, abnormal basal ganglia signal on brain MRI. |
| 8. Screening | Newborn tandem mass screening (elevated C3-acylcarnitine, increased C3/C2 ratio). Included in Korean national newborn screening. False positives: differentiation from methylmalonic acidemia needed. MMA and PA screened simultaneously. |
| 9. Diagnosis | Plasma amino acids (elevated glycine), urine organic acids (methylcitric acid·3-OH-propionic acid·propionylglycine), PCC enzyme activity (leukocytes·fibroblasts), PCCA·PCCB gene NGS. Differentiate from MMA. |
| 10. Treatment | Protein restriction (restriction of isoleucine·valine·threonine·methionine), L-carnitine supplementation, acute phase: glucose·insulin·management of hyperammonemia (Na-benzoate·N-carbamylglutamate). mRNA therapy (clinical trials). Liver transplantation. |
| 11. Prognosis | Neurological prognosis often poor (recurrent metabolic crises + basal ganglia damage). Cardiomyopathy is a major cause of death. After liver transplantation, fewer metabolic crises·improved quality of life. With long-term survival, QTc prolongation monitoring essential. |
| 12. Prevention | Newborn tandem mass screening, genetic counseling, PGT-M. Affected individuals: emergency protocol during catabolic stress, infection prevention (pneumococcal·influenza vaccination), regular cardiac evaluation. |
| 13. References | Childs B et al. Idiopathic hyperglycinemia and hyperglycinuria. Pediatrics. 1961;27:522-538 … and 9 other papers |
The history of propionic acidemia (PA) begins in 1961, when the American pediatrician Barton Childs and colleagues first reported a case with ketoacidosis and hyperglycinemia as "idiopathic hyperglycinemia and hyperglycinuria". At the time, the cause of the disease was mistakenly thought to be abnormal glycine metabolism, but it was later revealed that ketoacidosis and overproduction of propionic acid are the main mechanisms. In 1968, Hsia et al. first identified deficiency of propionyl-CoA carboxylase (PCC) activity as the cause of PA, establishing the biochemical understanding of the disease.
In the 1970s–80s, characteristic metabolites such as methylcitric acid, 3-hydroxypropionic acid, and propionylglycine were identified in urine organic acid analysis of PA patients as biochemical markers of PA. During this period it was also found that L-carnitine deficiency occurs frequently in PA patients and that carnitine supplementation helps treatment. In the 1980s–90s, the causative genes of PA, PCCA (chromosome 13, encoding the PCC α-subunit) and PCCB (chromosome 3, encoding the PCC β-subunit), were cloned·identified.
As newborn screening based on tandem mass spectrometry (TMS) spread from the mid-1990s, elevation of propionylcarnitine (C3-acylcarnitine), a biochemical indicator of PA, was established as a marker for early diagnosis. This made early diagnosis and treatment possible before symptom onset, laying the foundation for preemptively preventing acute metabolic crises in PA patients. In Korea as well, a system for early detection of PA in the neonatal period was established after national tandem mass screening was introduced in 2006.
From the 2000s, cardiomyopathy, basal ganglia damage, pancreatitis, bone marrow suppression, and others began to be systematically described as long-term complications of PA, and liver transplantation became established as a treatment option for PA. Since the 2010s, a dual mRNA therapeutic (mRNA-3927, encoding PCCA+PCCB simultaneously) has been developed and is in clinical trials (SUNRISE study), presenting a new paradigm for PA treatment.
Propionic acidemia is an organic acidemia caused by functional deficiency of propionyl-CoA carboxylase (PCC), located in the mitochondria. PCC is a carboxylase that uses biotin as a cofactor and catalyzes the conversion of propionyl-CoA to methylmalonyl-CoA. When this reaction is blocked, propionyl-CoA and its downstream metabolites accumulate in cells and blood, causing various toxicities.
PCC is an enzyme with an α₆β₆ dodecamer structure composed of six α-subunits encoded by the PCCA gene (13q32.3) and six β-subunits encoded by the PCCB gene (3q22.3). Each α-subunit is responsible for biotin carboxylation activity, and the β-subunit is responsible for substrate specificity and carboxyltransferase activity. When a pathogenic mutation occurs in either PCCA or PCCB, assembly or function of the entire PCC complex is impaired, resulting in PA.
The main sources of propionyl-CoA, the substrate of PCC, are as follows: (1) metabolism of branched-chain amino acids (isoleucine, valine); (2) metabolism of amino acids (threonine, methionine); (3) β-oxidation of odd-chain fatty acids; (4) cholesterol side-chain degradation; (5) anaerobic fermentation products of gut bacteria. When propionyl-CoA generated by these pathways cannot be converted to methylmalonyl-CoA because of PCC deficiency and accumulates, propionyl-CoA reacts with oxaloacetate, a tricarboxylic acid cycle intermediate, to produce methylcitric acid, and combines with carnitine to form propionylcarnitine (C3-acylcarnitine). 3-Hydroxypropionic acid and propionylglycine are also representative urinary metabolites. Propionic acid and its metabolites (a) inhibit key enzymes of the mitochondrial TCA cycle, impairing energy metabolism; (b) inhibit N-acetylglutamate synthase (NAGS) of the urea cycle, causing hyperammonemia; (c) cause hyperglycinemia through inhibition of the glycine cleavage system; and (d) cause direct neurotoxicity (damage to the basal ganglia striatum) and oxidative stress.
Propionic acidemia follows autosomal recessive inheritance and is expressed when there are pathogenic variants in both alleles of the PCCA or PCCB gene. Hundreds of pathogenic variants have been reported in both PCCA (13q32.3) and PCCB (3q22.3), and most are private variants. Various types, including missense, nonsense, deletion, insertion and splicing variants, have been reported; their correlation with phenotype has been studied in part but is generally of low predictive value. Residual PCC enzyme activity shows a rough correlation with phenotypic severity, with higher residual enzyme activity tending toward a milder phenotype.
High prevalence due to founder effects is observed in certain ethnic groups and regions. In Saudi Arabia, the prevalence of PA is very high at about 1/2,500–5,000 owing to consanguineous marriage, and the c.1218_1231del deletion mutation of the PCCB gene is a common founder mutation. A specific mutation of the PCCA gene is also found at relatively high frequency in the Greenland Inuit population. The PCCA/PCCB mutation spectrum in Korean and East Asian populations has been reported only to a limited extent, with mainly private variants identified sporadically. Worldwide, the proportions of PCCA and PCCB variants are roughly similar, although in some populations one predominates.
The worldwide prevalence of propionic acidemia is estimated at about 1/100,000–1/500,000 based on newborn tandem mass screening data, with large regional variation. It is about 1/100,000–1/200,000 in Western Europe and the United States, and markedly higher at 1/2,500–5,000 in countries where consanguineous marriage is common, such as Saudi Arabia. Relatively high prevalence is also reported in the Greenland Inuit population. Because of its autosomal recessive nature, the sex distribution is equal between males and females.
In Korea, several PA patients have been diagnosed early every year through tandem mass newborn screening since 2006. The number of registered patients in Korea is known to be in the tens, but accurate domestic prevalence data are actually lacking. In the rare disease statistics of the Health Insurance Review & Assessment Service (HIRA), PA is listed as a disease eligible for Special Copayment Reduction under V117. Before the introduction of tandem mass screening, diagnosis was made after symptom onset, so many patients experienced acute metabolic crises or diagnosis itself was delayed; now, with rapid confirmation and initiation of treatment after a positive screen, prognosis is improving.
The pathophysiology of propionic acidemia can be summarized as intramitochondrial accumulation of propionyl-CoA due to PCC deficiency and the generation of secondary toxic metabolites. The specific toxic mechanisms are as follows.
Impaired energy metabolism: Propionyl-CoA reacts abnormally with oxaloacetate, the substrate of citrate synthase, to produce methylcitric acid and sequesters oxaloacetate. This depletes TCA cycle substrates, reducing ATP production and causing a cellular energy crisis. The brain (basal ganglia, striatum), myocardium and bone marrow cells, which have high energy requirements, are particularly vulnerable. Hyperammonemia: Propionyl-CoA inhibits N-acetylglutamate synthase (NAGS), reducing production of N-acetylglutamate (NAG). Because NAG is an essential activator of carbamoyl phosphate synthetase (CPS1), the first enzyme of the urea cycle, reduced NAG → decreased CPS1 activity → urea cycle dysfunction → elevated blood ammonia results. Hyperglycinemia: Propionyl-CoA directly inhibits the glycine cleavage system (GCS), impairing glycine degradation and raising blood glycine concentration. Carnitine deficiency: Propionyl-CoA forms an ester bond with carnitine to form propionylcarnitine (C3-AC), which is excreted in urine, causing secondary carnitine deficiency. Carnitine deficiency further reduces energy production by impairing intramitochondrial transport of long-chain fatty acids. Direct neurotoxicity and oxidative stress: Propionic acid itself and methylcitric acid are directly toxic to neurons and induce oxidative stress through increased generation of reactive oxygen species (ROS). This causes selective damage to the basal ganglia (particularly the striatum) and underlies long-term motor dysfunction.
Acute neonatal onset (classic form): Infants appear normal immediately after birth, but symptoms appear within 24–72 hours after the start of feeding. Poor feeding, lethargy, vomiting and hypotonia are the initial symptoms, progressing rapidly to metabolic ketoacidosis, hyperammonemia, seizures and coma. Without treatment, death can occur in the neonatal period. When blood ammonia is markedly elevated (>500 μmol/L), there is a risk of residual severe brain damage.
Long-term complications: In surviving patients, recurrent acute metabolic crises (triggered by catabolic stress) are common, especially in infancy, and additional neurologic damage accumulates with each crisis. The main long-term complications are as follows. (1) Neurologic complications: intellectual disability, developmental delay, movement disorders (dyskinesia, dystonia and stroke-like episodes due to basal ganglia damage), seizures. (2) Cardiomyopathy: dilated cardiomyopathy or QT interval prolongation (QTc prolongation) commonly occurs in PA patients and can cause sudden cardiac death. Cardiomyopathy is associated with both acute metabolic crises and chronic propionic acid toxicity. (3) Bone marrow suppression: pancytopenia (thrombocytopenia, neutropenia, anemia) occurs and is explained by impaired energy metabolism in bone marrow cells. (4) Pancreatitis: acute pancreatitis is not uncommonly associated. (5) Growth failure, decreased bone mineral density and optic nerve abnormalities are also reported as long-term complications.
Biochemical findings: On tandem mass screening or confirmatory testing, elevated C3-acylcarnitine (propionylcarnitine) is the most specific marker. The C3/C2 ratio (propionylcarnitine/acetylcarnitine) is particularly markedly elevated in PA. On plasma amino acid analysis, elevated glycine is characteristic. On urine organic acid analysis (GC-MS), methylcitric acid, 3-hydroxypropionic acid, propionylglycine and others are markedly increased. Elevated blood ammonia (hyperammonemia), elevated blood glycine, elevated blood ketone bodies and metabolic acidosis (low pH, increased anion gap) are found in the acute phase. Decreased blood carnitine (total carnitine, free carnitine) and an increased acylcarnitine ratio are also characteristic.
Hematologic findings: pancytopenia (leukopenia, thrombocytopenia, anemia). Cardiac findings: QTc prolongation on electrocardiogram; left ventricular hypertrophy or dilated cardiomyopathy on echocardiography. Brain MRI: in the acute phase, DWI hyperintensity and T2 hyperintensity changes in the basal ganglia (putamen, caudate nucleus) and internal capsule (selective basal ganglia damage). In the chronic phase, basal ganglia atrophy and white matter signal abnormalities may be observed. MRI findings become more pronounced after acute stroke-like dyskinetic episodes.
Propionic acidemia is a major target disease of newborn tandem mass screening. PA is included in the national newborn screening program implemented in Korea since 2006, in which the acylcarnitine profile is analyzed from dried blood spots (DBS) collected at 48–72 hours after birth. The main screening indicators are as follows. (1) Elevated C3-acylcarnitine (propionylcarnitine): the most specific tandem mass screening indicator for PA. (2) Increased C3/C2 ratio: increased propionylcarnitine/acetylcarnitine ratio. However, because elevated C3-acylcarnitine also occurs commonly in methylmalonic acidemia (MMA) as well as PA, differentiation is required. PA and MMA are distinguished by urine organic acid analysis (presence or absence of methylmalonic acid excretion), blood vitamin B12 levels, cobalamin response testing and so on. When screening is positive, immediate referral for confirmatory testing and initiation of treatment if needed are recommended, and starting treatment before symptom onset is very important for improving neurologic prognosis.
Propionic acidemia is confirmed in the following steps. (1) Plasma amino acid analysis: marked elevation of glycine is characteristic of PA. (2) Serum and urine acylcarnitine analysis: marked elevation of C3-acylcarnitine (propionylcarnitine). (3) Urine organic acid analysis (GC-MS): massive excretion of methylcitric acid, 3-hydroxypropionic acid and propionylglycine is the key diagnostic finding of PA. If methylmalonic acid is not increased, PA is more likely than MMA. (4) Measurement of PCC enzyme activity: measured in peripheral blood leukocytes or skin fibroblasts. In PA, enzyme activity is reduced to less than 5% of normal. (5) Molecular genetic testing: NGS panel testing of the PCCA and PCCB genes. Final confirmation when pathogenic variants are identified in both alleles. (6) Differential diagnosis: methylmalonic acidemia (MMA) — C3-AC elevation is common to both but they are distinguished by the presence or absence of methylmalonic acid excretion; other organic acidemias causing ketoacidosis; neonatal sepsis; urea cycle disorders (isolated hyperammonemia). (7) Cardiac evaluation: after confirmation, evaluate for associated cardiomyopathy with echocardiography and electrocardiography (QTc measurement). (8) Brain MRI: evaluation of basal ganglia damage when neurologic abnormalities are present.
Treatment of propionic acidemia is divided into acute-phase treatment and long-term maintenance treatment.
Treatment of acute metabolic crisis: (1) Temporary cessation of protein intake: block the supply of propionyl-CoA precursors (isoleucine, valine, threonine, methionine) for 24–48 hours. (2) High-energy glucose and lipid administration: provide sufficient calories (glucose + lipid emulsion) to suppress catabolism, with insulin co-administered if needed. (3) Management of hyperammonemia: when blood ammonia is >200 μmol/L, administer sodium benzoate and sodium phenylacetate or N-carbamylglutamate (carglumic acid). N-carbamylglutamate is useful for hyperammonemia in PA through a mechanism of bypassing NAGS and directly activating CPS1 to restart the urea cycle. (4) In severe hyperammonemia (>500 μmol/L) or metabolic instability, perform hemodialysis for rapid ammonia removal. (5) Intravenous L-carnitine to promote propionylcarnitine excretion and replenish carnitine.
Long-term maintenance treatment: Protein restriction (restriction of isoleucine, valine, threonine and methionine, the precursor amino acids of propionyl-CoA) with special formula and a low-protein diet is the foundation. Continuous L-carnitine supplementation (50–100 mg/kg/day) prevents carnitine deficiency and promotes propionylcarnitine excretion. In some patients, antimicrobials (metronidazole or neomycin) are given intermittently to suppress propionic acid production by gut bacteria. Liver transplantation is indicated in patients with recurrent acute metabolic crises, progressive cardiomyopathy or uncontrolled metabolic abnormalities. After transplantation, acute metabolic crises decrease markedly and dietary restrictions may be partly relaxed, but PCC deficiency persists in extrahepatic tissues (brain, heart), so it is not a complete cure. mRNA-3927 (a dual PCCA+PCCB mRNA lipid nanoparticle formulation) is a new drug currently in clinical trials, a therapy based on the principle of directly restoring PCCA and PCCB protein expression in the liver.
The prognosis of propionic acidemia varies greatly depending on the timing of diagnosis, phenotypic severity and treatment adherence. Overall, the neurologic prognosis of PA is often poorer than that of MMA or IVA. Recurrent acute metabolic crises, especially hyperammonemic episodes in the neonatal period or infancy, cause irreversible basal ganglia damage and developmental delay. Dyskinesia, dystonia and stroke-like episodes due to basal ganglia damage are reported in about 30% of PA patients.
Cardiomyopathy is one of the most important causes of death in PA patients, and sudden cardiac death can occur due to dilated cardiomyopathy or QTc prolongation. Therefore, regular echocardiographic and electrocardiographic monitoring is essential in all PA patients. After liver transplantation, acute metabolic crises decrease markedly and quality of life improves, but reversal of neurologic and cardiac complications that have already occurred is difficult. Some PA patients detected early by screening and properly managed from the neonatal period show near-normal development, but they are a minority, and long-term neurodevelopmental monitoring remains necessary. In adult PA patients, cognitive decline and mental health problems such as anxiety and depression are frequent.
Primary prevention of propionic acidemia is achieved through genetic counseling and prenatal/preimplantation genetic testing. With two carrier parents, each pregnancy has a 25% chance of being affected, and an affected fetus can be diagnosed by PGT-M or prenatal DNA testing. The key element of secondary prevention is early diagnosis through newborn tandem mass screening and rapid initiation of treatment. Patients who start treatment before symptom onset have a significantly better neurologic prognosis than those who do not. In affected patients, catabolic stress situations (fever, infection, surgery, fasting, excessive exercise) are the main triggers of acute metabolic crisis, so recognizing them and promptly implementing a prepared emergency protocol is the key to preventing metabolic crises. Infection prevention measures such as pneumococcal and influenza vaccination also indirectly help reduce the frequency of metabolic crises. Early detection and treatment of cardiomyopathy through regular echocardiographic and electrocardiographic monitoring is important for preventing sudden cardiac death.